Compile Data Set for Download or QSAR
Report error Found 516 Enz. Inhib. hit(s) with all data for entry = 8704
TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413625BDBM413625(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413725BDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50: 0.260nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413721BDBM413721(4-{[(2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl...)
Affinity DataIC50: 0.310nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413626BDBM413626(4-[(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413727BDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50: 0.340nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413719BDBM413719(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413654BDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413745BDBM413745(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413610BDBM413610(4-{[(2S)-2-{4-[5-Chloro-2-(1,3-oxazol-5-yl)phenyl]...)
Affinity DataIC50: 0.400nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413722BDBM413722(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.460nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413726BDBM413726(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.5nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413652BDBM413652(4-{[(2S)-4-tert-Butoxy-2-{4-[5-chloro-2-(1,2-oxazo...)
Affinity DataIC50: 0.530nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413720BDBM413720(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.550nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413777BDBM413777(US10421742, Example 170 | N-(Quinoxalin-6-yl)-(2S)...)
Affinity DataIC50: 0.550nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413724BDBM413724(N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-...)
Affinity DataIC50: 0.560nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413725BDBM413725(N-(Quinoxalin-6-yl)-(2S)-2-{4-[5-chloro-2-(1H-tetr...)
Affinity DataIC50: 0.570nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413746BDBM413746(2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-metho...)
Affinity DataIC50: 0.590nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413773BDBM413773(US10421742, Example 166 | 4-({2-[4-{5-Chloro-2-[4-...)
Affinity DataIC50: 0.620nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413847BDBM413847(US10421742, Example 240 | 4-{[(2S)-2-{4-[5-Chloro-...)
Affinity DataIC50: 0.640nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413851BDBM413851(US10421742, Example 244 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413797BDBM413797(US10421742, Example 190 | 4-[({4-[5-Chloro-2-(1H-t...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413793BDBM413793(US10421742, Example 186 | 2-{4-[5-Chloro-2-(4-chlo...)
Affinity DataIC50: 0.650nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413723BDBM413723(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.660nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413770BDBM413770(US10421742, Example 163 | N-(Quinoxalin-6-yl)-(2S)...)
Affinity DataIC50: 0.700nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413633BDBM413633(4-[(2-{4-[5-Chloro-2-(1,3,4-oxadiazol-2-yl)phenyl]...)
Affinity DataIC50: 0.700nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413748BDBM413748(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.710nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413749BDBM413749(4-({2-[4-{5-Chloro-2-[4-(difluoromethyl)-1H-1,2,3-...)
Affinity DataIC50: 0.710nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413743BDBM413743(5-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.720nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413796BDBM413796(US10421742, Example 189 | N-(Quinoxalin-6-yl)-2-{4...)
Affinity DataIC50: 0.730nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413858BDBM413858(US10421742, Example 251 | 4-({(2S)-2-[4-{5-Chloro-...)
Affinity DataIC50: 0.740nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413792BDBM413792(US10421742, Example 185 | N-(Quinoxalin-6-yl)-2-{4...)
Affinity DataIC50: 0.75nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413747BDBM413747(N-(Quinoxalin-6-yl)-2-{4-[5-chloro-2-(1H-tetrazol-...)
Affinity DataIC50: 0.760nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413817BDBM413817(US10421742, Example 210 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.780nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413775BDBM413775(US10421742, Example 168 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.780nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413727BDBM413727((2S)-2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-...)
Affinity DataIC50: 0.780nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413840BDBM413840(US10421742, Example 233 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.790nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413861BDBM413861(US10421742, Example 254 | 2-{4-[5-Chloro-2-(4-chlo...)
Affinity DataIC50: 0.810nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413779BDBM413779(US10421742, Example 172 | 2-{4-[5-Chloro-2-(1H-tet...)
Affinity DataIC50: 0.820nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413641BDBM413641(US10421742, Example 35 | 4-[(2-{4-[5-Chloro-2-(4,5...)
Affinity DataIC50: 0.830nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413737BDBM413737((2S)-2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1...)
Affinity DataIC50: 0.840nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413744BDBM413744(4-{[2-{4-[5-Chloro-2-(1H-tetrazol-1-yl)phenyl]-5-m...)
Affinity DataIC50: 0.840nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413864BDBM413864(US10421742, Example 257 | (2S)-2-{4-[5-Chloro-2-(4...)
Affinity DataIC50: 0.850nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413772BDBM413772(US10421742, Example 165 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.860nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413850BDBM413850(US10421742, Example 243 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.870nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413846BDBM413846(US10421742, Example 239 | 4-({2-[4-{5-Chloro-2-[4-...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413849BDBM413849(US10421742, Example 242 | 4-{[(2S)-2-{4-[5-Chloro-...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413844BDBM413844(US10421742, Example 237 | (2S)-2-[4-{5-Chloro-2-[4...)
Affinity DataIC50: 0.890nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413842BDBM413842(US10421742, Example 235 | 4-({(2S)-2-[4-{5-Chloro-...)
Affinity DataIC50: 0.920nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413696BDBM413696(4-[(2-{4-[5-Chloro-2-(3-methyl-1,2,4-oxadiazol-5-y...)
Affinity DataIC50: 0.920nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 413706BDBM413706(2-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)p...)
Affinity DataIC50: 0.960nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
US Patent

Displayed 1 to 50 (of 516 total ) | Next | Last >>
Jump to: